Viridian Therapeutics

US · VRDN #2731 by market cap Listed 1970

18.28 +0.06 +0.33%

Live - 5344 symbols - heartbeat 41s ago · 2026-10-07 21:23

After-hours 18.22 -0.33%

Overnight 18.07 -1.15%

Market cap: 2.07B
P/E (TTM): -5.38
P/B: 3.67
EPS: -3.32
Div yield: 0.00%
52W pos: 24%

Reader sentiment Are you bullish or bearish on VRDN?

Anonymous reader poll. Unscientific, not investment advice.

About Viridian Therapeutics

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Founded: 2006
CEO: Mr. Stephen Mahoney
Employees: 252
Headquarters: Waltham, Massachusetts, United States of America
Fiscal year end: 12-31
Website: viridiantherapeutics.com

Company profile

Exchange: US
Symbol: VRDN
Market-cap rank: #2731
Listing date: 1970-01-01
Market cap: 2.07B
Float cap: 1.84B
Shares out: 113.29M
Float shares: 100.65M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-07 21:23:26 · For reference only, not investment advice and not tailored to your situation.